- Home
- BRT vs ENTA Comparison
BRT vs ENTA Comparison
Compare BRT & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- ENTA
- Stock Information
- Founded
- BRT 1972
- ENTA 1995
- Country
- BRT United States
- ENTA United States
- Employees
- BRT N/A
- ENTA N/A
- Industry
- BRT Real Estate Investment Trusts
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- ENTA Health Care
- Exchange
- BRT Nasdaq
- ENTA Nasdaq
- Market Cap
- BRT 281.9M
- ENTA 316.2M
- IPO Year
- BRT N/A
- ENTA 2013
- Fundamental
- Price
- BRT $14.64
- ENTA $10.96
- Analyst Decision
- BRT Strong Buy
- ENTA Strong Buy
- Analyst Count
- BRT 1
- ENTA 5
- Target Price
- BRT $19.50
- ENTA $21.00
- AVG Volume (30 Days)
- BRT 46.2K
- ENTA 470.2K
- Earning Date
- BRT 11-06-2025
- ENTA 11-17-2025
- Dividend Yield
- BRT 6.83%
- ENTA N/A
- EPS Growth
- BRT N/A
- ENTA N/A
- EPS
- BRT N/A
- ENTA N/A
- Revenue
- BRT $98,350,000.00
- ENTA $64,806,000.00
- Revenue This Year
- BRT N/A
- ENTA $0.07
- Revenue Next Year
- BRT $4.12
- ENTA N/A
- P/E Ratio
- BRT N/A
- ENTA N/A
- Revenue Growth
- BRT 2.71
- ENTA N/A
- 52 Week Low
- BRT $14.17
- ENTA $4.09
- 52 Week High
- BRT $20.22
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- BRT 41.45
- ENTA 54.80
- Support Level
- BRT $14.41
- ENTA $10.44
- Resistance Level
- BRT $15.09
- ENTA $11.34
- Average True Range (ATR)
- BRT 0.35
- ENTA 0.63
- MACD
- BRT 0.03
- ENTA -0.07
- Stochastic Oscillator
- BRT 35.71
- ENTA 62.00
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.